Cas:10094-41-4 cis-3-hexenyl 2-methylbutanoate 97+% manufacturer & supplier

Chemical Name:cis-3-hexenyl 2-methylbutanoate 97+%

CAS.NO:10094-41-4

Synonyms:2-Methylbutyric acid 3-hexenyl ester;hex-3;Butanoicacid,2-methyl-,3-hexenylester;hex-3-enyl2;Hex-3-enyl-2-methylbutyrat;hex-3-enyl;2-methyl-butanoicaci3-hexenylester;hex-3-enyl2-methylbutyrate;3-HEXENYL2-METHYLBUTANOATE

Molecular Formula:C₁₁H₂₀O₂

Molecular Weight:184.27500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:231.8ºC at 760 mmHg

Density:0.887g/cm3

Index of Refraction:1.44

PSA:26.30000

Exact Mass:184.14600

LogP:2.93200

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3077 9/PG 3

Packing Group:

Contact us for information like 2-Methylbutyric acid 3-hexenyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-HEXENYL2-METHYLBUTANOATE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-HEXENYL2-METHYLBUTANOATE Use and application,2-Methylbutyric acid 3-hexenyl ester technical grade,usp/ep/jp grade.

Related News: The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. cis-3-hexenyl 2-methylbutanoate 97+% manufacturer The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market. cis-3-hexenyl 2-methylbutanoate 97+% supplier This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. cis-3-hexenyl 2-methylbutanoate 97+% vendor The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. cis-3-hexenyl 2-methylbutanoate 97+% factory The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.